Goldman Sachs Lifts Estimates and Price Target on Teva Pharma (TEVA)
More News related to TEVA
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
- Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
- Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
- Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of Three COPAXONE(R)-Related Patents
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
More News related to Analyst Comments
- Citi Boosts Target on McDonald's (MCD) to $64, Maintains Hold
- Canaccord Adams Reiterates a 'Buy' on Veeco Instruments (VECO); Raises PT & Estimates
- Canaccord Adams Reiterates a 'Buy' on NBTY (NTY); Raises PT
- Canaccord Adams Reiterates a 'Buy' on Protalix BioTherapeutics (PLX)
- Canaccord Adams Reiterates a 'Buy' on Rosetta Resources (ROSE); Raises PT
Goldman Sachs lifts estimates and its price target on Teve Pharma (Nasdaq: TEVA) to $54. The firm sees solid growth through 2012 and reiterates their Conviction Buy List rating.
The firm raised 2009 EPS 2% to $3.36, FY10 was lifted 3% to $4.42, FY11 was lifted 1% to $4.72 and new FY12 EPS of $5.34.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Analyst CommentsStocks Mentioned
-0.47Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
